A Theranostic Approach in Selective Internal Radiation Therapy: Comparison
View Latest Version
Please note this is a comparison between Version 7 by Jessie Wu and Version 6 by Jessie Wu.

Selective internal radiation therapy (SIRT) is one of the treatment options for liver tumors. Microspheres labelled with a therapeutic radionuclide (90Y or 166Ho) are injected into the liver artery feeding the tumor(s), usually achieving a high tumor absorbed dose and a high tumor control rate. This treatment adopts a theranostic approach with a mandatory simulation phase, using a surrogate to radioactive microspheres (99mTc-macroaggregated albumin, MAA) or a scout dose of 166Ho microspheres, imaged by SPECT/CT.

  • SIRT
  • MAA
  • 166Ho

1. Introduction

Selective internal radiation therapy (SIRT) is a treatment option for liver tumors by delivering radioactive microspheres in the tumors’ feeding arteries, leading to very high absorbed doses to tumors and usually achieving a high tumor control rate [1]. Hepatic tumors are mainly vascularized by the liver artery as opposed to the healthy liver, whose blood supply is preferentially ensured by the portal vein [2]. This unique characteristic is the milestone of SIRT efficacy. By injecting radioactive microspheres in the liver artery or any of its branches, tumor(s) receive very high absorbed doses while sparing the healthy liver.
Three types of radioactive microspheres are commercially available, differing by their physical and radioactive characteristics: yttrium-90 (90Y)-resin microspheres (Sir-Spheres®, Sirtex Medical GmbH, Sydney, Australia), 90Y-glass microspheres (Therasphere®, Boston Scientific, Boston, MA, USA), and holmium-166 (166Ho)-poly-L-lactic acid (PLLA) microspheres (QuiremSpheres®, Quirem Medical B.V., Deventer, The Netherlands) [3]. Only Sir-Spheres® and Therasphere® have FDA approval for the U.S. market.
The SIRT procedure applies a theranostic approach by using similar radiopharmaceuticals agents for both therapy planning and treatment [4]. During the first step, the treatment is simulated using a surrogate: 99mTc-macroaggregated albumin (MAA) or a scout dose of the radioactive microspheres (166Ho-scout dose), enabling a selection of patients who have good tumor targeting and no absolute contraindications for treatment such as excessive lung shunt and digestive uptake. These radionuclides emit low energy gamma rays, allowing for detection by nuclear imaging systems to precisely localize the distribution in the liver or in non-targeted tissues. In particular, 3D imaging using single photon emission computed tomography combined with CT scan (SPECT/CT) allows an accurate evaluation of the MAA distribution (MAA SPECT/CT) for evaluating extra hepatic arterial shunting to limit the risks of lung and gastrointestinal complications during treatment [5][6].

2. 99mTc-macroaggregated Albumin Particles as a Surrogate to Radioactive Microspheres: Physical and Technical Limitations

Prior to SIRT, a mandatory simulation phase is performed with diagnostic liver arteriography for mapping the tumor vascularization coil embolization if needed (e.g., in case of proximity to arterial digestive branches) and ends with the injection of MAA particles through the angiographic catheter, well positioned in the vascular territory of the tumor(s). This angiographic procedure is followed by planar and SPECT/CT imaging of the MAA distribution. Like 90Y or 166Ho microspheres, MAA is trapped in the arterial microvasculature of the liver and can therefore simulate the distribution of the microspheres. Nevertheless, MAA is not the perfect surrogate because of their physical characteristics, which differ from those of the therapeutic microspheres.
Compared to microspheres, MAA particles have a variable shape, a different size distribution (90% within 10 to 90 μm) with a lower mean size (15 μm versus 25–32 μm), and are injected in much smaller numbers (Table 1) [3][7][8][9]. These differences can explain some discrepancy between the MAA and the microsphere biodistribution, especially the risk of increased shunt to the lungs with MAA.
Table 1. Main physical characteristics of MAA and radioactive microspheres.
Characteristics 99mTc-MAA Particles 90Y-Resin

Microspheres		 90Y-Glass

Microspheres		 166Ho-PLLA

Microspheres
Diameter (mean) 15 μm 32 μm 25 μm 30 μm
Usual number of injected particles (in millions) 0.3–0.7 50 * 4 * 30 *
* For a 3 GBq activity at usual calibration time.
The smallest MAA particles can pass through the liver capillaries and be responsible for over-estimation of the lung shunt [10]. Nevertheless, an excessive MAA uptake in the lungs indicates high hepato-pulmonary shunting and hence a relative contraindication for SIRT (risks of radiation-induced pneumonitis and fibrosis) [11]. A lung shunt superior to 20% or an estimated lung absorbed dose in excess of 30 Gy are contraindications for SIRT [12]. Moreover, these physical differences can be responsible for distribution variations in the healthy and tumor(s) compartments. More precisely, the variable size of MAA particles seems to be a limiting factor in tumor absorbed dose prediction. Indeed, by simulating the treatment with a scout dose of microspheres instead of MAA particles, tumor absorbed doses were more precisely predicted [13][14].
In addition, the lack of precise replication of positioning between the liver arteriographies at the time of simulation and treatment can result in a mismatch between liver distribution of MAA and microspheres. Both procedures require the use of similar angiographic catheters and positioning as well as a well-matched orientation in the artery lumen, and end with an injection of particles at a distance from arterial bifurcations, after controlling for the absence of any vasospasm [15][16]. In addition, MAA particles must also be injected slowly (over 20 s) to better match with the treatment procedure [17].

3. Accuracy of 99mTc-Macroaggregated Albumin Single Photon Emission Computed Tomography/CT for Predicting Tumor and Non-Tumoral Whole Liver Absorbed Doses

Some previous studies compared the simulated MAA tumor and non-tumoral liver absorbed doses to the real absorbed doses calculated with post-therapy 90Y imaging. The non-tumoral whole liver absorbed dose (NTWLD) refers to the whole healthy liver (targeted or not by SIRT) as defined recently by the EANM dosimetry committee [7]. In these studies, the strength of the correlation between the MAA absorbed doses and the 90Y absorbed doses was assessed and quantified using the Pearson coefficient R, ranging from 0 (no linear correlation) to 1 (perfect linear correlation) [18]. Figure 1 represents the results of previous studies where the Pearson test was used for comparing the biodistribution of MAA and the radioactive microspheres. Regarding the estimate of tumor absorbed doses, they demonstrated a variable correlation, with a Pearson coefficient ranging from 0.56 to 0.91. Nevertheless, a large majority of these studies demonstrated a moderate correlation (R < 0.7), and only two studies with a small number of patients showed a higher correlation (R close to 0.9). Another parameter was also compared, i.e., tumor to liver ratio (TNR), and will be discussed further.
Jcm 11 07245 g002 550
Figure 1. Pearson coefficient correlations between doses estimated by MAA SPECT/CT and post 90Y SIRT imaging [14][19][20][21][22][23][24][25][26][27][28][29]. (A) blue: non-tumoral liver absorbed dose (NTLD), referring to the non-tumoral whole liver or to the non-tumoral liver targeted by SIRT (*). (A) red: tumor absorbed dose (TD). (B) purple: tumor to normal liver ratio uptake (TNR). Abscissa legend: patients and tumor numbers of each study referenced in bracket. Note the better correlation obtained for the NTLD versus TD or TNR.
Some studies also measured the agreement between these absorbed doses using Bland–Altman analyses [30]. By measuring the differences between these pairs, this statistical test evaluated the risk of errors in MAA imaging for calculating the absorbed doses, after defining the limits of agreement (95% confidence interval). Table 2 summarizes studies performing Bland–Altman analyses and where the relative confidence intervals were available or estimated from absolute values. All these studies demonstrated a similar risk of under- and over-estimation of the tumor absorbed dose (similar plotting over and under the reference X axis). Moreover, the limits of agreement were large in a majority of these studies, with a maximum error over 100% of the tumor absorbed dose estimation in 3 studies.
Table 2. Predictive value of pre-therapy MAA imaging for estimating TD and NTWLD (using Bland–Altman analyses for measuring the extremes).
Studies Type of Microspheres Post Therapy Imaging Type of Tumors Nb of Patients Nb of Tumors TD

Estimation

(Relative 95% CI) +		 NTWLD

Estimation

(Relative 95% CI) +
Kafrouni et al. 2019 [25] glass 90Y PET/CT HCC 23 24 −29%; +29% −34%; +34%

Tc-Macroaggregated AAlbumin Tumor Absorbed Doses Correlate with Clinical Outcome after SIRelective Internal Radiation Therapy

Despite the low accuracy of MAA SPECT/CT for predicting tumor absorbed doses, numerous data are available for demonstrating a strong relationship between the MAA tumor absorbed dose and SIRT efficacy. In particular, when a certain MAA tumor absorbed dose threshold was achieved, the radiological response and the patient outcome were significantly improved. Table 3 summarizes studies showing this correlation between MAA tumor absorbed doses and the clinical outcome, demonstrating the high significance of this pre-therapy dosimetry. Nevertheless, a distinction must be made between determining an exact tumor absorbed dose and predicting a high level of tumor absorbed dose. Based on previous data, an exact tumor absorbed dose cannot be predicted from MAA imaging, but its level (low versus high) can be determined with high accuracy. When a high tumor absorbed dose is simulated with MAA SPECT/CT, the tumor will receive a high tumor absorbed dose in a large majority of the cases, achieving a threshold of high tumor absorbed dose. In a series of patients treated for HCC by resin microspheres, a threshold dose of 100 Gy simulated with MAA imaging was achieved in 90% of them on 90Y post-therapy imaging [23].
Table 3. MAA tumor absorbed doses thresholds correlated to SIRT efficacy.
Studies + Microspheres Tumors Number of Patients Tumor Absorbed Dose Threshold Predictor of Tumor Response Predictor of Better Survival (Median)
Chiesa et al. 2011 [38] glass HCC 46 ≥257 Gy 85% NA
Richetta et al. 2019 [21]
Garin et al. 2012 resin [39]90Y PET/CT HCC 10 10 −39%; +33% −24%; +31%
glass HCC 36 ≥205 Gy 100% 18 mo ° Jafargholi Rangraz et al. 2020 [22] resin 90Y PET/CT HCC and mets 31 67 −169%; +146% −30%, +23%
(vs. 9 mo) Jadoul et al.

2020 [31]		 resin and glass 90Y PET/CT HCC and mets 57 137 −100%; +100% −36%, +36%
d’Abadie et al. 2021 [23] resin 90Y PET/CT HCC and mets 66 171 −76%; +320% −19%, +24%
HCC: hepatocellular carcinoma; mets: metastases; TD: Tumor absorbed dose; Nb: number; NTWLD: non-tumoral whole liver absorbed dose; + In some studies, absolute 95% CI were converted in relative 95% CI (comparison to the mean).
Regarding the prediction of the normal liver absorbed dose, all studies were congruent and demonstrated the accuracy of MAA SPECT/CT. The NTWLD calculated with pre-therapy MAA SPECT/CT was strongly correlated with the NTWLD calculated with post-therapy 90Y PET/CT, with a Pearson coefficient over 0.9 in all studies (Figure 1). Moreover, Bland–Altman analyses confirmed this good agreement with a maximal deviation ranging from −36% to +36% (Table 2).
Using alternative methods of comparison in 16 patients, Thomas et al. showed similar results, demonstrating a lack of prediction of the tumor absorbed dose but a highly reliable prediction of the normal liver absorbed dose with MAA imaging [32].

4. Value of 99mTc-Macroaggregated Albumin Single Photon Emission Computed Tomography (SPECT)/CT to Predict the Tumor to Normal Liver Uptake Ratio

Some recent studies compared pre-therapy MAA imaging to post-therapy 90Y imaging using the tumor to normal liver uptake ratio (TNR). As previously mentioned, tumors are preferentially vascularized by the liver artery while the healthy liver is vascularized by the portal vein; therefore, TNR is usually greater than 1 [33]. This ratio is also directly correlated to the tumor absorbed dose [34]. The results of these studies are summarized in Figure 1B). They demonstrated results similar to the prediction of tumor absorbed doses. Indeed, TNR was moderately predicted, with a Pearson coefficient ranging from 0.53 to 0.9.
Other studies were performed using an alternative Spearman’s rank test, also demonstrating a moderate correlation in a study analyzing colorectal metastases (ρ = 0.51) and in a study pooling a mix of tumors (ρ = 0.65) [34][35].
Nevertheless, a high TNR uptake seems very well predicted by MAA imaging. In a study evaluating 171 tumors, MAA SPECT/CT predicted a high TNR ratio (≥1.5) with an accuracy of 85% [23]. Moreover, in liver metastases from colorectal cancer (CRC), a TNR ratio superior to 1.7 was a predictor of SIRT efficacy [34]. Therefore, the TNR ratio estimated from MAA imaging can generally select patients suitable for SIRT, avoiding ineffective procedures for patients with TNR ratios close to 1 [36][37].

5. 99m

Mazzaferro et al. 2013
[
40
] glass HCC 52 ≥500 Gy 80% NA
Chiesa et al. 2015 [41] glass HCC 52 ≥217 Gy 100% NA
Garin et al. 2017 [42] glass HCC 85 ≥205 Gy 98% 21 mo °
(vs. 6.5 mo)
Bourien et al. 2019 [43] glass CGC 64 ≥260 Gy 88% * 28.2 mo °
(vs. 11.4 mo)
Lam et al. 2013 [44] resin CRC 25 ≥55 Gy NA 32.8 mo °
(vs. 7.2 mo)
Chansanti et al. 2017 [45] resin NET 15 ≥191 Gy 83% NA
Piasecki et al. 2018 [34] resin CRC 21 ≥70 Gy 99% NA
Hermann et al. 2020 [46] resin HCC 121 ≥100 Gy 72% 14.1 mo °
(vs. 6.8 mo)
Son et al. 2021 [27] resin HCC 34 ≥125 Gy 86% NA
HCC: hepatocellular carcinoma; CGC: cholangiocarcinoma; NET: neuroendocrine tumors; CRC: colorectal cancer; NA: not available; * subgroup of 29 patients; + Studies with mixed tumor types and without distinction of types of treatment (resin or glass) were excluded. ° differences statistically significant (p < 0.05).

References

  1. Bastiaannet, R.; Kappadath, S.C.; Kunnen, B.; Braat, A.; Lam, M.; de Jong, H. The physics of radioembolization. EJNMMI Phys. 2018, 5, 22.
  2. Filippi, L.; Braat, A.J. Theragnostics in primary and secondary liver tumors: The need for a personalized approach. Q. J. Nucl. Med. Mol. Imaging 2021, 65, 353–370.
  3. D’Abadie, P.; Hesse, M.; Louppe, A.; Lhommel, R.; Walrand, S.; Jamar, F. Microspheres Used in Liver Radioembolization: From Conception to Clinical Effects. Molecules 2021, 26, 3966.
  4. Gomes Marin, J.F.; Nunes, R.F.; Coutinho, A.M.; Zaniboni, E.C.; Costa, L.B.; Barbosa, F.G.; Queiroz, M.A.; Cerri, G.G.; Buchpiguel, C.A. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Radiographics 2020, 40, 1715–1740.
  5. Georgiou, M.F.; Kuker, R.A.; Studenski, M.T.; Ahlman, P.P.; Witte, M.; Portelance, L. Lung shunt fraction calculation using (99m)Tc-MAA SPECT/CT imaging for (90)Y microsphere selective internal radiation therapy of liver tumors. EJNMMI Res. 2021, 11, 96.
  6. Theysohn, J.M.; Ruhlmann, M.; Muller, S.; Dechene, A.; Best, J.; Haubold, J.; Umutlu, L.; Gerken, G.; Bockisch, A.; Lauenstein, T.C. Radioembolization with Y-90 Glass Microspheres: Do We Really Need SPECT-CT to Identify Extrahepatic Shunts? PLoS ONE 2015, 10, e0137587.
  7. Chiesa, C.; Sjogreen-Gleisner, K.; Walrand, S.; Strigari, L.; Flux, G.; Gear, J.; Stokke, C.; Gabina, P.M.; Bernhardt, P.; Konijnenberg, M. EANM dosimetry committee series on standard operational procedures: A unified methodology for (99m)Tc-MAA pre- and (90)Y peri-therapy dosimetry in liver radioembolization with (90)Y microspheres. EJNMMI Phys. 2021, 8, 77.
  8. Reinders, M.T.M.; Smits, M.L.J.; van Roekel, C.; Braat, A. Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. Semin. Nucl. Med. 2019, 49, 237–243.
  9. Al-Janabi, M.A.; Yousif, Z.M.; Kadim, A.H.; Al-Salem, A.M. A new technique for the preparation of ready-to-use macroaggregated albumin (MAA) kits to be labelled with 99mTc for lung scanning. Int. J. Appl. Radiat. Isot. 1983, 34, 1473–1478.
  10. Elschot, M.; Nijsen, J.F.; Lam, M.G.; Smits, M.L.; Prince, J.F.; Viergever, M.A.; van den Bosch, M.A.; Zonnenberg, B.A.; de Jong, H.W. ((9)(9)m)Tc-MAA overestimates the absorbed dose to the lungs in radioembolization: A quantitative evaluation in patients treated with (1)(6)(6)Ho-microspheres. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1965–1975.
  11. Leung, T.W.; Lau, W.Y.; Ho, S.K.; Ward, S.C.; Chow, J.H.; Chan, M.S.; Metreweli, C.; Johnson, P.J.; Li, A.K. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int. J. Radiat. Oncol. Biol. Phys. 1995, 33, 919–924.
  12. Ward, T.J.; Tamrazi, A.; Lam, M.G.; Louie, J.D.; Kao, P.N.; Shah, R.P.; Kadoch, M.A.; Sze, D.Y. Management of High Hepatopulmonary Shunting in Patients Undergoing Hepatic Radioembolization. J. Vasc. Interv. Radiol. 2015, 26, 1751–1760.
  13. Smits, M.L.J.; Dassen, M.G.; Prince, J.F.; Braat, A.; Beijst, C.; Bruijnen, R.C.G.; de Jong, H.; Lam, M. The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 798–806.
  14. Kokabi, N.; Webster, L.A.; Elsayed, M.; Switchenko, J.M.; Chen, B.; Brandon, D.; Galt, J.; Sethi, I.; Cristescu, M.; Kappadath, C.; et al. Accuracy and Safety of Scout Dose Resin Yttrium-90 Microspheres for Radioembolization Therapy Treatment Planning: A prospective single-arm clinical trial. J. Vasc. Interv. Radiol. 2022, 33, 1578–1587.
  15. Garin, E.; Rolland, Y.; Laffont, S.; Edeline, J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 559–575.
  16. D’Abadie, P.; Walrand, S.; Goffette, P.; Amini, N.; Maanen, A.V.; Lhommel, R.; Jamar, F. Antireflux catheter improves tumor targeting in liver radioembolization with resin microspheres. Diagn. Interv. Radiol. 2021, 27, 768–773.
  17. Garin, E.; Guiu, B.; Edeline, J.; Rolland, Y.; Palard, X. Trans-arterial Radioembolization Dosimetry in 2022. Cardiovasc. Interv. Radiol. 2022, 45, 1608–1621.
  18. Schober, P.; Boer, C.; Schwarte, L.A. Correlation Coefficients: Appropriate Use and Interpretation. Anesth. Analg. 2018, 126, 1763–1768.
  19. Song, Y.S.; Paeng, J.C.; Kim, H.C.; Chung, J.W.; Cheon, G.J.; Chung, J.K.; Lee, D.S.; Kang, K.W. PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy: Single Cohort Comparison With Pretreatment Planning on (99m)Tc-MAA Imaging and Correlation with Treatment Efficacy. Medicine 2015, 94, e945.
  20. Gnesin, S.; Canetti, L.; Adib, S.; Cherbuin, N.; Silva Monteiro, M.; Bize, P.; Denys, A.; Prior, J.O.; Baechler, S.; Boubaker, A. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison. J. Nucl. Med. 2016, 57, 1672–1678.
  21. Richetta, E.; Pasquino, M.; Poli, M.; Cutaia, C.; Valero, C.; Tabone, M.; Paradisi, B.P.; Pacilio, M.; Pellerito, R.E.; Stasi, M. PET-CT post therapy dosimetry in radioembolization with resin (90)Y microspheres: Comparison with pre-treatment SPECT-CT (99m)Tc-MAA results. Phys. Med. 2019, 64, 16–23.
  22. Jafargholi Rangraz, E.; Tang, X.; Van Laeken, C.; Maleux, G.; Dekervel, J.; Van Cutsem, E.; Verslype, C.; Baete, K.; Nuyts, J.; Deroose, C.M. Quantitative comparison of pre-treatment predictive and post-treatment measured dosimetry for selective internal radiation therapy using cone-beam CT for tumor and liver perfusion territory definition. EJNMMI Res. 2020, 10, 94.
  23. D’Abadie, P.; Walrand, S.; Hesse, M.; Amini, N.; Lhommel, R.; Sawadogo, K.; Jamar, F. Accurate non-tumoral 99mTc-MAA absorbed dose prediction to plan optimized activities in liver radioembolization using resin microspheres. Phys. Med. 2021, 89, 250–257.
  24. Haste, P.; Tann, M.; Persohn, S.; LaRoche, T.; Aaron, V.; Mauxion, T.; Chauhan, N.; Dreher, M.R.; Johnson, M.S. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT. J. Vasc. Interv. Radiol. 2017, 28, 722–730.
  25. Kafrouni, M.; Allimant, C.; Fourcade, M.; Vauclin, S.; Guiu, B.; Mariano-Goulart, D.; Ben Bouallegue, F. Analysis of differences between (99m)Tc-MAA SPECT- and (90)Y-microsphere PET-based dosimetry for hepatocellular carcinoma selective internal radiation therapy. EJNMMI Res. 2019, 9, 62.
  26. Debebe, S.A.; Adjouadi, M.; Gulec, S.A.; Franquiz, J.; McGoron, A.J. (90) Y SPECT/CT quantitative study and comparison of uptake with pretreatment (99 m) Tc-MAA SPECT/CT in radiomicrosphere therapy. J. Appl. Clin. Med. Phys. 2019, 20, 30–42.
  27. Son, M.H.; Ha, L.N.; Bang, M.H.; Bae, S.; Giang, D.T.; Thinh, N.T.; Paeng, J.C. Diagnostic and prognostic value of (99m)Tc-MAA SPECT/CT for treatment planning of (90)Y-resin microsphere radioembolization for hepatocellular carcinoma: Comparison with planar image. Sci. Rep. 2021, 11, 3207.
  28. Villalobos, A.; Cheng, B.; Wagstaff, W.; Sethi, I.; Bercu, Z.; Schuster, D.M.; Brandon, D.C.; Galt, J.; Kokabi, N. Tumor-to-Normal Ratio Relationship between Planning Technetium-99 Macroaggregated Albumin and Posttherapy Yttrium-90 Bremsstrahlung SPECT/CT. J. Vasc. Interv. Radiol. 2021, 32, 752–760.
  29. Meine, T.C.; Brunkhorst, T.; Werncke, T.; Schutze, C.; Vogel, A.; Kirstein, M.M.; Dewald, C.L.A.; Becker, L.S.; Maschke, S.K.; Kretschmann, N.; et al. Comparison of the Uptake of Hepatocellular Carcinoma on Pre-Therapeutic MDCT, CACT, and SPECT/CT, and the Correlation with Post-Therapeutic PET/CT in Patients Undergoing Selective Internal Radiation Therapy. J. Clin. Med. 2021, 10, 3837.
  30. Giavarina, D. Understanding Bland Altman analysis. Biochem. Med. 2015, 25, 141–151.
  31. Jadoul, A.; Bernard, C.; Lovinfosse, P.; Gerard, L.; Lilet, H.; Cornet, O.; Hustinx, R. Comparative dosimetry between (99m)Tc-MAA SPECT/CT and (90)Y PET/CT in primary and metastatic liver tumors. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 828–837.
  32. Thomas, M.A.; Mahvash, A.; Abdelsalam, M.; Kaseb, A.O.; Kappadath, S.C. Planning dosimetry for (90) Y radioembolization with glass microspheres: Evaluating the fidelity of (99m) Tc-MAA and partition model predictions. Med. Phys. 2020, 47, 5333–5342.
  33. Ilhan, H.; Goritschan, A.; Paprottka, P.; Jakobs, T.F.; Fendler, W.P.; Todica, A.; Bartenstein, P.; Hacker, M.; Haug, A.R. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors. J. Nucl. Med. 2015, 56, 1654–1660.
  34. Piasecki, P.; Narloch, J.; Brzozowski, K.; Ziecina, P.; Mazurek, A.; Budzynska, A.; Korniluk, J.; Dziuk, M. The Predictive Value of SPECT/CT imaging in colorectal liver metastases response after 90Y-radioembolization. PLoS ONE 2018, 13, e0200488.
  35. Rhee, S.; Kim, S.; Cho, J.; Park, J.; Eo, J.S.; Park, S.; Lee, E.; Kim, Y.H.; Choe, J.G. Semi-Quantitative Analysis of Post-Transarterial Radioembolization (90)Y Microsphere Positron Emission Tomography Combined with Computed Tomography (PET/CT) Images in Advanced Liver Malignancy: Comparison With (99m)Tc Macroaggregated Albumin (MAA) Single Photon Emission Computed Tomography (SPECT). Nucl. Med. Mol. Imaging 2016, 50, 63–69.
  36. D’Abadie, P.; Walrand, S.; Lhommel, R.; Hesse, M.; Borbath, I.; Jamar, F. Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Curr. Oncol. 2022, 29, 2422–2434.
  37. Levillain, H.; Bagni, O.; Deroose, C.M.; Dieudonne, A.; Gnesin, S.; Grosser, O.S.; Kappadath, S.C.; Kennedy, A.; Kokabi, N.; Liu, D.M.; et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1570–1584.
  38. Chiesa, C.; Maccauro, M.; Romito, R.; Spreafico, C.; Pellizzari, S.; Negri, A.; Sposito, C.; Morosi, C.; Civelli, E.; Lanocita, R.; et al. Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: The experience of the National Tumor Institute of Milan. Q. J. Nucl. Med. Mol. Imaging 2011, 55, 168–197.
  39. Garin, E.; Lenoir, L.; Rolland, Y.; Edeline, J.; Mesbah, H.; Laffont, S.; Poree, P.; Clement, B.; Raoul, J.L.; Boucher, E. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: Preliminary results. J. Nucl. Med. 2012, 53, 255–263.
  40. Mazzaferro, V.; Sposito, C.; Bhoori, S.; Romito, R.; Chiesa, C.; Morosi, C.; Maccauro, M.; Marchiano, A.; Bongini, M.; Lanocita, R.; et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology 2013, 57, 1826–1837.
  41. Chiesa, C.; Mira, M.; Maccauro, M.; Spreafico, C.; Romito, R.; Morosi, C.; Camerini, T.; Carrara, M.; Pellizzari, S.; Negri, A.; et al. Radioembolization of hepatocarcinoma with (90)Y glass microspheres: Development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur. J. Nucl. Med. Mol. Imaging 2015, 42, 1718–1738.
  42. Garin, E.; Rolland, Y.; Pracht, M.; Le Sourd, S.; Laffont, S.; Mesbah, H.; Haumont, L.A.; Lenoir, L.; Rohou, T.; Brun, V.; et al. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization. Liver Int. 2017, 37, 101–110.
  43. Bourien, H.; Palard, X.; Rolland, Y.; Le Du, F.; Beuzit, L.; Uguen, T.; Le Sourd, S.; Pracht, M.; Manceau, V.; Lievre, A.; et al. Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: A large single-center experience. Eur. J. Nucl. Med. Mol. Imaging 2019, 46, 669–676.
  44. Lam, M.G.; Goris, M.L.; Iagaru, A.H.; Mittra, E.S.; Louie, J.D.; Sze, D.Y. Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT. J. Nucl. Med. 2013, 54, 2055–2061.
  45. Chansanti, O.; Jahangiri, Y.; Matsui, Y.; Adachi, A.; Geeratikun, Y.; Kaufman, J.A.; Kolbeck, K.J.; Stevens, J.S.; Farsad, K. Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT. J. Vasc. Interv. Radiol. 2017, 28, 1528–1535.
  46. Hermann, A.L.; Dieudonne, A.; Ronot, M.; Sanchez, M.; Pereira, H.; Chatellier, G.; Garin, E.; Castera, L.; Lebtahi, R.; Vilgrain, V.; et al. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with (90)Y in the SARAH Study. Radiology 2020, 296, 673–684.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback